Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Jesper van Breeschoten; Michel W. J. M. Wouters; Doranne L. Hilarius; John B. Haanen; Christian U. Blank; Maureen J. B. Aarts; Franchette W. P. J. van den Berkmortel; Jan-Willem B. de Groot; Geke A. P. Hospers; Ellen Kapiteijn; Djura Piersma; Roos S. van Rijn; Karijn P. M. Suijkerbuijk; Willeke A. M. Blokx; Bert-Jan J. ten Tije; Astrid A. M. van der Veldt; Art Vreugdenhil; Marye J. Boers-Sonderen; Alfonsus J. M. van den Eertwegh

doi:https://doi.org/10.1038/s41416-022-01772-z

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Jesper van Breeschoten, Michel W. J. M. Wouters, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Karijn P. M. Suijkerbuijk, Willeke A. M. Blokx, Bert-Jan J. ten Tije, Astrid A. M. van der Veldt, Art Vreugdenhil, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Original language	English
Pages (from-to)	1362
Number of pages	1
Journal	British journal of cancer
Volume	126
Issue number	9
Early online date	2022
DOIs	https://doi.org/10.1038/s41416-022-01772-z
Publication status	Published - 18 May 2022

Access to Document

https://doi.org/10.1038/s41416-022-01772-z

Cite this

van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J.-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., Tije, B.-J. J. T., Veldt, A. A. M. V. D., Vreugdenhil, A., Boers-Sonderen, M. J., & van den Eertwegh, A. J. M. (2022). Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). British journal of cancer, 126(9), 1362. https://doi.org/10.1038/s41416-022-01772-z

van Breeschoten, Jesper ; Wouters, Michel W. J. M. ; Hilarius, Doranne L. et al. / Correction : First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). In: British journal of cancer. 2022 ; Vol. 126, No. 9. pp. 1362.

@article{1df4a6ccd7264f08b77bdec0b10070ba,

title = "Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)",

abstract = "The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.",

author = "{van Breeschoten}, Jesper and Wouters, {Michel W. J. M.} and Hilarius, {Doranne L.} and Haanen, {John B.} and Blank, {Christian U.} and Aarts, {Maureen J. B.} and {van den Berkmortel}, {Franchette W. P. J.} and {de Groot}, {Jan-Willem B.} and Hospers, {Geke A. P.} and Ellen Kapiteijn and Djura Piersma and {van Rijn}, {Roos S.} and Suijkerbuijk, {Karijn P. M.} and Blokx, {Willeke A. M.} and Tije, {Bert-Jan J. ten} and Veldt, {Astrid A. M. van der} and Art Vreugdenhil and Boers-Sonderen, {Marye J.} and {van den Eertwegh}, {Alfonsus J. M.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2022.",

year = "2022",

month = may,

day = "18",

doi = "https://doi.org/10.1038/s41416-022-01772-z",

language = "English",

volume = "126",

pages = "1362",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "9",

}

van Breeschoten, J, Wouters, MWJM, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, J-WB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Blokx, WAM, Tije, B-JJT, Veldt, AAMVD, Vreugdenhil, A, Boers-Sonderen, MJ & van den Eertwegh, AJM 2022, 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)', British journal of cancer, vol. 126, no. 9, pp. 1362. https://doi.org/10.1038/s41416-022-01772-z

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). / van Breeschoten, Jesper; Wouters, Michel W. J. M.; Hilarius, Doranne L. et al.
In: British journal of cancer, Vol. 126, No. 9, 18.05.2022, p. 1362.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correction

T2 - First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

AU - van Breeschoten, Jesper

AU - Wouters, Michel W. J. M.

AU - Hilarius, Doranne L.

AU - Haanen, John B.

AU - Blank, Christian U.

AU - Aarts, Maureen J. B.

AU - van den Berkmortel, Franchette W. P. J.

AU - de Groot, Jan-Willem B.

AU - Hospers, Geke A. P.

AU - Kapiteijn, Ellen

AU - Piersma, Djura

AU - van Rijn, Roos S.

AU - Suijkerbuijk, Karijn P. M.

AU - Blokx, Willeke A. M.

AU - Tije, Bert-Jan J. ten

AU - Veldt, Astrid A. M. van der

AU - Vreugdenhil, Art

AU - Boers-Sonderen, Marye J.

AU - van den Eertwegh, Alfonsus J. M.

PY - 2022/5/18

Y1 - 2022/5/18

N2 - The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

AB - The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

UR - http://www.scopus.com/inward/record.url?scp=85125710952&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41416-022-01772-z

DO - https://doi.org/10.1038/s41416-022-01772-z

M3 - Comment/Letter to the editor

C2 - 35256756

SN - 0007-0920

VL - 126

SP - 1362

JO - British journal of cancer

JF - British journal of cancer

IS - 9

ER -

van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB et al. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). British journal of cancer. 2022 May 18;126(9):1362. Epub 2022. doi: https://doi.org/10.1038/s41416-022-01772-z

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Abstract

Access to Document

Other files and links

Cite this